|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP2R2B |
Gene summary for PPP2R2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP2R2B | Gene ID | 5521 |
| Gene name | protein phosphatase 2 regulatory subunit Bbeta | |
| Gene Alias | B55BETA | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q00005 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5521 | PPP2R2B | LZE4T | Human | Esophagus | ESCC | 1.25e-18 | 4.74e-01 | 0.0811 |
| 5521 | PPP2R2B | P10T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.28e-01 | 0.116 |
| 5521 | PPP2R2B | P11T-E | Human | Esophagus | ESCC | 1.20e-09 | 4.15e-01 | 0.1426 |
| 5521 | PPP2R2B | P12T-E | Human | Esophagus | ESCC | 1.13e-16 | 3.80e-01 | 0.1122 |
| 5521 | PPP2R2B | P15T-E | Human | Esophagus | ESCC | 9.35e-25 | 5.83e-01 | 0.1149 |
| 5521 | PPP2R2B | P26T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.25e-01 | 0.1276 |
| 5521 | PPP2R2B | P28T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.49e-01 | 0.1149 |
| 5521 | PPP2R2B | P30T-E | Human | Esophagus | ESCC | 1.56e-07 | 3.31e-01 | 0.137 |
| 5521 | PPP2R2B | P44T-E | Human | Esophagus | ESCC | 7.53e-03 | 1.38e-01 | 0.1096 |
| 5521 | PPP2R2B | P47T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.92e-01 | 0.1067 |
| 5521 | PPP2R2B | P52T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.45e-01 | 0.1555 |
| 5521 | PPP2R2B | P61T-E | Human | Esophagus | ESCC | 1.62e-06 | 1.67e-01 | 0.099 |
| 5521 | PPP2R2B | P79T-E | Human | Esophagus | ESCC | 2.08e-40 | 8.14e-01 | 0.1154 |
| 5521 | PPP2R2B | P130T-E | Human | Esophagus | ESCC | 5.00e-17 | 4.47e-01 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
| GO:00702624 | Esophagus | ESCC | peptidyl-serine dephosphorylation | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa051425 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
| hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa0514213 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP2R2B | SNV | Missense_Mutation | rs775290828 | c.386N>A | p.Arg129His | p.R129H | Q00005 | protein_coding | deleterious(0.01) | benign(0.019) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPP2R2B | SNV | Missense_Mutation | novel | c.179C>T | p.Thr60Met | p.T60M | Q00005 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.897) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP2R2B | SNV | Missense_Mutation | c.1123N>G | p.Leu375Val | p.L375V | Q00005 | protein_coding | tolerated(0.29) | benign(0.01) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPP2R2B | SNV | Missense_Mutation | c.317N>T | p.Ala106Val | p.A106V | Q00005 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPP2R2B | SNV | Missense_Mutation | c.565N>T | p.Arg189Cys | p.R189C | Q00005 | protein_coding | deleterious(0) | possibly_damaging(0.462) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPP2R2B | SNV | Missense_Mutation | c.217A>T | p.Thr73Ser | p.T73S | Q00005 | protein_coding | tolerated_low_confidence(0.19) | benign(0.005) | TCGA-A6-A567-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| PPP2R2B | SNV | Missense_Mutation | novel | c.716C>T | p.Thr239Ile | p.T239I | Q00005 | protein_coding | deleterious(0) | benign(0.196) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| PPP2R2B | SNV | Missense_Mutation | novel | c.1009N>T | p.Pro337Ser | p.P337S | Q00005 | protein_coding | deleterious(0.03) | benign(0.267) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPP2R2B | SNV | Missense_Mutation | novel | c.1462N>T | p.Pro488Ser | p.P488S | Q00005 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPP2R2B | SNV | Missense_Mutation | rs377462455 | c.40G>A | p.Glu14Lys | p.E14K | Q00005 | protein_coding | deleterious_low_confidence(0) | benign(0.006) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |